膝痹通方治疗早期膝骨关节炎肝肾亏虚证临床研究

Clinical study on Xibitong prescription in treating kneeosteoarthritis of early Ganshen Kuixu type

目的:探讨膝痹通方治疗早期膝骨关节炎肝肾亏虚证的临床疗效。方法:选取100例早期膝骨关节炎肝肾亏虚证患者,随机分为对照组、试验组各50例。试验组采用膝痹通方口服,对照组采用维固力联合扶他林口服。比较治疗前、治疗后、治疗后2周、治疗后4周两组WOMAC、VAS、Lequesne指数评分、基质金属蛋白酶13(MMP-13)水平。结果:试验组的治疗总有效率为86.0%,高于对照组的70.0%,差异有统计学意义(P<0.05)。治疗后两组的WOMAC评分、Lequesne总评分、VAS评分、MMP-13水平均低于治疗前,差异有统计学意义(均P<0.05)。试验组在治疗后、治疗后2周、治疗后4周的WOMAC总评分、VAS评分、Lequesne总评分、MMP-13表达均低于对照组,差异有统计学意义(均P<0.05)。结论:膝痹通方治疗早期膝骨关节炎肝肾亏虚证疗效较好,能改善患者膝关节功能,降低血清MMP-13表达,具有骨关节炎软骨基质的降解作用,有效阻止膝骨关节炎进展。

Objective:To investigate clinical efficacy of Xibitong prescription in treatment of knee osteoarthritis of early Ganshen Kuixu type.Methods:A total of 100 patients with knee osteoarthritis of early Ganshen Kuixu type were selected.They were randomly divided into control group and experimental group,50 cases in each group.The experimental group were taken orally with Xibitong prescription,and the control group were taken by weiguli combined with voltaren orally.The two groups of WOMAC,VAS,Lequesne,MMP-13 level were compared before treatment,after treatment,2 weeks and 4 weeks after treatment.Results:The effective rate of treatment in the experimental group was 86.0%,which was lower than 70.0%in the control group.The total effective rate of the two groups was statistically significant(P<0.05).After treatment,the WOMAC score and Lequesne total score,VAS score,and MMP-13 levels were lower than before treatment,difference statistically significant(all P<0.05).The total WOMAC score,VAS score,Lequesne score and MMP-13 expression of the experimental group were lower than those in the control group after treatment,2 weeks and 4 weeks after treatment,difference statistically significant(all P<0.05).Conclusion:Xibitong prescription has clear curative effect in the treatment of knee osteoarthritis in early Ganshen Kuixu type.It can reduce the expression level of serum MMP-13.It has significant effect on reducing degradation of osteoarthritis cartilage matrix,effectively prevent progression of osteoarthritis.